Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Effect of a multifactorial intervention on mortality in type 2 diabetes.

Gaede P, Lund-Andersen H, Parving HH, Pedersen O.

N Engl J Med. 2008 Feb 7;358(6):580-91. doi: 10.1056/NEJMoa0706245.

2.

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O.

N Engl J Med. 2003 Jan 30;348(5):383-93.

3.

Systematic review on urine albumin testing for early detection of diabetic complications.

Newman DJ, Mattock MB, Dawnay AB, Kerry S, McGuire A, Yaqoob M, Hitman GA, Hawke C.

Health Technol Assess. 2005 Aug;9(30):iii-vi, xiii-163. Review.

4.

Causes of death, incidence and risk factors of cardiovascular diseases in Thai type 2 diabetic patients: a 5 year follow-up study.

Leelawattana R, Rattarasarn C, Lim A, Soonthornpun S, Setasuban W.

Diabetes Res Clin Pract. 2003 Jun;60(3):183-9.

PMID:
12822563
6.

Intensified multifactorial intervention and cardiovascular outcome in type 2 diabetes: the Steno-2 study.

Pedersen O, Gaede P.

Metabolism. 2003 Aug;52(8 Suppl 1):19-23. Review.

PMID:
12939735
7.

Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).

Wilcox R, Kupfer S, Erdmann E; PROactive Study investigators.

Am Heart J. 2008 Apr;155(4):712-7. doi: 10.1016/j.ahj.2007.11.029. Epub 2008 Feb 21. Erratum in: Am Heart J. 2008 Aug;156(2):255.

PMID:
18371481
8.

[The Steno-2 study. Intensive multifactorial intervention reduces the occurrence of cardiovascular disease in patients with type 2 diabetes].

Gaede PH, Jepsen PV, Larsen JN, Jensen GV, Parving HH, Pedersen OB.

Ugeskr Laeger. 2003 Jun 23;165(26):2658-61. Danish. No abstract available.

PMID:
12886549
9.

Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.

Warfarin Antiplatelet Vascular Evaluation Trial Investigators, Anand S, Yusuf S, Xie C, Pogue J, Eikelboom J, Budaj A, Sussex B, Liu L, Guzman R, Cina C, Crowell R, Keltai M, Gosselin G.

N Engl J Med. 2007 Jul 19;357(3):217-27.

10.

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.

Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE.

N Engl J Med. 2005 Mar 31;352(13):1293-304. Epub 2005 Mar 7.

11.

Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial.

Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, Hague W, Beller E, Arulchelvam M, Baker J, Tonkin A; LIPID Study Group.

Diabetes Care. 2003 Oct;26(10):2713-21.

PMID:
14514569
12.

Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.

Dailey G.

Clin Ther. 2011 Jun;33(6):665-78. doi: 10.1016/j.clinthera.2011.04.025. Review.

PMID:
21704233
13.
14.

Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.

James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL; SCOUT Investigators.

N Engl J Med. 2010 Sep 2;363(10):905-17. doi: 10.1056/NEJMoa1003114.

15.

Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.

Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R; SEAS Investigators.

N Engl J Med. 2008 Sep 25;359(13):1343-56. doi: 10.1056/NEJMoa0804602. Epub 2008 Sep 2.

16.

Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis.

Zhang C, Sun A, Zhang P, Wu C, Zhang S, Fu M, Wang K, Zou Y, Ge J.

Diabetes Res Clin Pract. 2010 Feb;87(2):211-8. doi: 10.1016/j.diabres.2009.09.029. Epub 2009 Oct 23.

PMID:
19853947
17.
18.

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24.

19.

Treatment of microalbuminuria in patients with type 2 diabetes mellitus.

Jerums G, MacIsaac RJ.

Treat Endocrinol. 2002;1(3):163-73. Review.

PMID:
15799209
20.

Interactive effect of retinopathy and macroalbuminuria on all-cause mortality, cardiovascular and renal end points in Chinese patients with Type 2 diabetes mellitus.

Tong PC, Kong AP, So WY, Yang X, Ng MC, Ho CS, Ma RC, Ozaki R, Ng V, Chow CC, Lam CW, Chan JC, Cockram CS.

Diabet Med. 2007 Jul;24(7):741-6. Epub 2007 Apr 2.

PMID:
17403120

Supplemental Content

Support Center